Mylan generic drug to compete with Salix’s key product Colazal

Generic drug developer Mylan Inc. said Monday the U.S. Food and Drug Administration approved its version of Salix Pharmaceuticals Ltd.'s key drug Colazal. via Penticton Herald

Comments

• Find It

• Recently Written

  • test post
  • Type 2 Diabetes And Obesity Research - ZenBio, Inc. Awarded $1.38…
  • Fact Sheets About Thyroid Disorders Published By NIDDK
  • Genentech Issues Dear Healthcare Provider Letter Regarding A Reported …
  • Behavioral Modification Programs Help Obese Children Manage Their Weight
  • Loss of the protein target of lithium disrupts normal mouse embryonic heart development
  • Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien Study
  • FDA: No Lou Gehrig’s disease risk with statins
  • Repurposing Of Enbrel For Alzheimer’s Disease
  • Researchers Propose Minocycline As A Promising Drug For Patients With Fragile X Syndrome

• Categories

  • News

• Monthly Archives

  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • December 1969

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • FDA MedWatch
  • Health Canada RSS
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2008 Drug Injury News